Compare CRSP & ALH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | ALH |
|---|---|---|
| Founded | 2013 | 1908 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.1B |
| IPO Year | 2016 | 2025 |
| Metric | CRSP | ALH |
|---|---|---|
| Price | $50.34 | $23.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 8 |
| Target Price | ★ $85.42 | $31.13 |
| AVG Volume (30 Days) | ★ 1.3M | 768.0K |
| Earning Date | 11-02-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | $289,590,000.00 | ★ $1,709,237,000.00 |
| Revenue This Year | $910.97 | $6.65 |
| Revenue Next Year | $277.83 | $6.19 |
| P/E Ratio | ★ N/A | $36.72 |
| Revenue Growth | ★ 9169.85 | 13.31 |
| 52 Week Low | $44.12 | $18.64 |
| 52 Week High | $63.45 | $28.23 |
| Indicator | CRSP | ALH |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 69.60 |
| Support Level | $50.02 | $22.92 |
| Resistance Level | $60.68 | $25.43 |
| Average True Range (ATR) | 2.44 | 0.73 |
| MACD | 0.06 | 0.25 |
| Stochastic Oscillator | 36.10 | 98.89 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Alliance Laundry Holdings Inc is a designer and manufacturer of commercial laundry systems, serving diverse international markets. The company offers premium, durable laundry equipment under brands like Speed Queen, UniMac, Huebsch, Primus, IPSO, and others. It serves commercial laundry needs across healthcare, hotels, laundromats, and residential markets. Revenue is generated through the sale of commercial-grade laundry systems and service parts across two geographic segments, North America and International, and into the three end markets of OPL, Vended, and Commercial In-Home.